Posterior Reversible Encephalopathy Syndrome After Intravitreal Bevacizumab Injection in Patient with Choroidal Neovascular Membrane Secondary to Age-Related Maculopathy

被引：13

作者：

Artunay, Ozgur ^{[1
]}

Yuzbasioglu, Erdal ^{[1
]}

Rasier, Rifat ^{[1
]}

Sengul, Alper ^{[1
]}

Bahcecioglu, Halil ^{[1
]}

机构：

[1] Istanbul Bilim Univ, Dept Ophthalmol, Istanbul, Turkey

来源：

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS | 2010年 / 26卷 / 03期

关键词：

MACULAR DEGENERATION; AVASTIN;

D O I：

10.1089/jop.2009.0148

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

The posterior reversible encephalopathy syndrome (PRES), a complex of cerebral disorders including headache, seizures, visual disturbances, is associated with a variety of conditions in which blood pressure rises acutely. Arterial hypertension can occur in systemic administration of bevacizumab. A few cases of systemic injection of bevazicumab-induced PRES have been reported. In this article, we first report on a patient who developed PRES following intravitreal bevazicumab.

引用

页码：301 / 303

页数：3

共 8 条

[1] Pharmacokinetics of intravitreal bevackumab (avastin) [J].

Bakri, Sophie J. ;

Snyder, Melissa R. ;

Reid, Joel M. ;

Pulido, Jose S. ;

Singh, Ravinder J. .

OPHTHALMOLOGY, 2007, 114 (05) :855-859

[2] Reversible posterior leukoencephalopathy syndrome associated with bevacizumab/doxorubicin regimen [J].

Burki, Franck ;

Badie, Kattalin ;

Bartoli, Philippe ;

Bernard, Pascale ;

Montastruc, Jean Louis ;

Bagheri, Haleh .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 65 (05) :793-794

[3] Intravitreal bevacizumab (avastin) treatment of neovascular age-related macular degeneration [J].

Emerson, M. Vaughn ;

Lauer, Andreas K. ;

Flaxel, Christina J. ;

Wilson, David J. ;

Francis, Peter J. ;

Stout, J. Timothy ;

Emerson, Geoffrey G. ;

Schlesinger, Thomas K. ;

Nolte, Susan K. ;

Klein, Michael L. .

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2007, 27 (04) :439-444

[4] The International Intravitreal Bevacizumab Safety Survey: using the Internet to assess drug safety worldwide [J].

Fung, A. E. ;

Rosenfeld, P. J. ;

Reichel, E. .

BRITISH JOURNAL OF OPHTHALMOLOGY, 2006, 90 (11) :1344-1349

[5]

OCZAN C, 2006, NEW ENGL J MED, V9, P980

[6] The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension [J].

Rasier, R. ;

Artunay, O. ;

Yuzbasioglu, E. ;

Sengul, A. ;

Bahcecioglu, H. .

EYE, 2009, 23 (08) :1714-1718

[7] Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin®) for neovascular age-related macular degeneration [J].

Rosenfeld, PJ ;

Moshfeghi, AA ;

Puliafito, CA .

OPHTHALMIC SURGERY LASERS & IMAGING, 2005, 36 (04) :331-335

[8] Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer [J].

Willett, CG ;

Boucher, Y ;

di Tomaso, E ;

Duda, DG ;

Munn, LL ;

Tong, RT ;

Chung, DC ;

Sahani, DV ;

Kalva, SP ;

Kozin, SV ;

Mino, M ;

Cohen, KS ;

Scadden, DT ;

Hartford, AC ;

Fischman, AJ ;

Clark, JW ;

Ryan, DP ;

Zhu, AX ;

Blaszkowsky, LS ;

Chen, HX ;

Shellito, PC ;

Lauwers, GY ;

Jain, RK .

NATURE MEDICINE, 2004, 10 (02) :145-147

← 1 →